Immunic Inc Stock Price, News & Analysis

Immunic, Inc. (Nasdaq: IMUX) announced favorable results from its Phase 1 clinical trial of IMU-856, indicating a positive safety, tolerability, and pharmacokinetic profile. The trial included single ascending doses (SAD) and multiple ascending doses (MAD) in healthy subjects, where no maximum tolerated dose was reached, and no serious adverse events occurred. The trial is ongoing with patients suffering from celiac disease. Results showed stable plasma concentrations and support the potential of IMU-856 as a first-in-class oral therapy for celiac disease and other gastrointestinal conditions.

Immunic, Inc. (Nasdaq: IMUX) announced its participation in several investor conferences throughout September 2022. Key events include the Citi's 17th Annual BioPharma Conference on September 7-8 in Boston, where CEO Daniel Vitt and Head of Investor Relations Jessica Breu will attend. The Wells Fargo 2022 Healthcare Conference will feature Dr. Vitt in a fireside chat on September 9 at 9:45 am EDT, with a live broadcast available on the company's website. Additionally, Breu will present at the 2022 Ladenburg Thalmann Healthcare Conference on September 29 at 1:00 pm EDT in New York.

Immunic, Inc. (NASDAQ: IMUX) announced receipt of a Notice of Allowance from the USPTO for its patent application 16/646130, covering the composition-of-matter of IMU-856. This patent is expected to provide protection until at least 2038. The license for IMU-856 was acquired from Daiichi Sankyo in 2020. The drug targets intestinal barrier function, aiming to treat gastrointestinal diseases. A phase 1 clinical trial for IMU-856 in celiac disease has commenced, with safety data expected in Q3 2022. This milestone enhances Immunic's intellectual property portfolio.

Immunic (Nasdaq: IMUX) announced its financial results for Q2 2022 and provided updates on its clinical programs. The company reported a net loss of $21.9 million for the quarter, with cash reserves of $88.1 million expected to sustain operations through Q4 2023. Key upcoming clinical milestones include initial activity results for IMU-935 in psoriasis expected in Q4 2022 and unblinded safety data for IMU-856 anticipated in Q3 2022. Immunic remains optimistic about the potential of vidofludimus calcium in multiple sclerosis despite previous challenges in ulcerative colitis trials.

Immunic, Inc. (Nasdaq: IMUX), a biopharmaceutical company focused on chronic inflammatory and autoimmune diseases, announced CEO Daniel Vitt will speak at the 2022 Wedbush PacGrow Virtual Healthcare Conference on August 9, 2022, at 8:00 am ET. The conference runs from August 9-10. A live webcast will be accessible on the company's website, with an archived replay available for 90 days. Immunic is advancing therapies targeting conditions like multiple sclerosis and psoriasis.

Immunic, Inc. (Nasdaq: IMUX) will announce its financial results for Q2 2022, ending June 30, on August 4, 2022, prior to U.S. market opening. A webcast will follow at 8:00 am ET, with registration available through their website. The company develops selective oral immunology therapies aimed at chronic inflammatory and autoimmune diseases, with products like IMU-838 for multiple sclerosis and IMU-935 for psoriasis and prostate cancer.

Immunic, Inc. (Nasdaq: IMUX) announced the appointment of Maria Törnsén to its Board of Directors, effective July 5, 2022. Törnsén brings 20 years of global commercial experience in the biopharmaceutical sector. She replaces Jan Van den Bossche, who stepped down after six years. Chairman Duane Nash emphasized Törnsén's sales and marketing expertise will enhance the company's strategic focus as it advances its clinical programs, particularly the phase 3 ENSURE program targeting multiple sclerosis with its lead asset, vidofludimus calcium.

Immunic, Inc. (Nasdaq: IMUX) announced its participation in three key industry conferences this July focused on immunology therapies. From July 5-6, members will attend the 3rd FORUM Science & Health: Medicine of the Future in Fürstenfeldbruck, Germany. Notably, Evelyn Peelen, Ph.D., will present findings on IMU-935, an oral IL-17 inhibitor, at the 16th World Immune Regulation Meeting from July 6-9 in Davos, Switzerland. Additionally, Dr. Peelen will discuss IMU-935 at the B & T Cell-Mediated Autoimmune Disease Drug Development Summit from July 26-28 in Boston.

On June 15, 2022, Immunic, Inc. (Nasdaq: IMUX) announced the publication of positive results from its phase 2 EMPhASIS trial of vidofludimus calcium in patients with relapsing-remitting multiple sclerosis (RRMS). The study demonstrated that treatment significantly reduced MRI lesion counts by 62% and 70% for 45 mg and 30 mg doses, respectively, compared to placebo. The drug was found to be safe and well-tolerated, with no significant adverse effects. Following these findings, Immunic is progressing with its phase 2 CALLIPER trial and phase 3 ENSURE program, aiming to explore further potential of vidofludimus.